USPTO serial 98241061
Serial No. 98241061
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 28, 2025
- Examiner
- HELLMAN, ELI J
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 98241061?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
Alexandra MacKay STITES & HARBISON PLLC401 COMMERCE STREETSUITE 800NASHVILLE, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes | ACTIVE | — |
| 042 | Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services | ACTIVE | — |
| 044 | Medical services; providing medical and pharmaceutical advice; gene bank services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 28, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 28, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 10, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 10, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 4, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 9, 2024 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Aug 6, 2024 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 23, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 22, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 22, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 2, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Nov 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 30, 2023 | NWAP | NEW APPLICATION ENTERED | — |